MDCO The Medicines Company

+0  (0%)
Previous Close 52.89
Open 52.99
Price To book 5.73
Market Cap 3.74B
Shares 70,644,000
Volume 1,116,460
Short Ratio 9.92
Av. Daily Volume 1,964,570

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated mid-2017.
Development discontinued due to poor effiacy - November 7, 2016.
Acute coronary syndrome (ACS)
Phase 3 data met endpoints June 2016. NDA filing due early 2017
Complicated urinary tract infections (cUTI)
CRL April 30 2014. Approved June 22 2015
Reduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI)
Approved April 30, 2015.
Approved April 30, 2015.
Acute postoperative pain
Approved August 6 2014 under priority review.

Latest News

  1. The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam
  2. The Medicines Company to Announce First-Quarter 2017 Financial Results on April 26, 2017
  3. Regeneron's Evinacumab Gets Breakthrough Therapy by FDA
  4. Federal appeals court rules Mylan can proceed with generic Angiomax
  5. Former Ariad CEO joins a familiar face on board of The Medicines Co., hinting at a sale
  6. Three Small Caps to Buy for the Second Quarter
  7. 5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them
  8. Why Is Medicines Company (MDCO) Down 5.1% Since the Last Earnings Report?
  9. The Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors
  10. The Medicines Company to Present at Needham Healthcare Conference
  11. The 3 Best Cholesterol Drug Stocks to Buy in 2017
  12. Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can
  13. How This Company Is Taking on Amgen
  14. Alnylam's LDL-Lowering Drug Positive in Phase II Study
  15. Esperion And Medicines Co. Recover From Amgen-Induced Pitfall
  16. Amgen discounts cholesterol drug, but payers want more
  17. How to Trade the Week's Most Active Stocks--Rite Aid, Amgen, MuleSoft and More
  18. The Biggest Loser: Amgen Drops 6.4%
  19. Esperion's Dive On Amgen Heart Study 'Counterintuitive' On Pricing
  20. Amgen Tanks On Heart Study; Shares Of Other Drugmakers Tumble